

Pierfrancesco Tassone, MD

I. Personal Data

Work:

Translational Medical Oncology Unit
Department of Experimental and Clinical
Medicine
Magna Graecia University
Campus Salvatore Venuta
Viale Europa
88100 Catanzaro, Italy
Ph: +39-0961-3647029

E-mail: tassone@unicz.it

Biographical sketch

I. Education

- | | |
|------|---|
| 1991 | Board certified in Medical Oncology, <i>Federico II</i> University, Naples, Italy |
| 1988 | Medical Degree, University of Reggio Calabria, Medical School of Catanzaro, Italy |

II. Academic Appointments

- | | |
|----------------|--|
| 2010 - present | Adjunct Professor , College of Science and Technology, Temple University, Philadelphia, USA |
| 2008 - present | Director , Translational Medical Oncology and Referral Center for Genetic Counselling and Innovative Treatments in Medical Oncology, <i>Magna Græcia</i> University, Catanzaro, Italy |
| 2006 - present | Full Professor of Medical Oncology , <i>Magna Græcia</i> University, Catanzaro, Italy |
| 2002 - 2005 | Research Associate , Jerome Lipper Multiple Myeloma Center and Department of Medical Oncology - VA Healthcare system, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA |

2001 - 2002	Research Associate , Department of Medicine/School of Medicine, Coomprehensive Cancer Center, University of California, San Diego, La Jolla, CA, USA
2001 - 2006	Associate Professor of Medical Oncology , <i>Magna Græcia</i> University, Catanzaro, Italy
1994 - 1996	Clinical Associate , Division of Medical Oncology, National Cancer Center, Milan, Italy
1991 - 1993	Research Associate , Experimental Oncology Division A, Fondazione Pascale National Cancer Center, Naples, Italy
1991 - 2001	Assistant Professor , <i>Magna Græcia</i> University, Catanzaro, Italy
1989 - 1990	Postdoctoral fellow , Tumor Immunology, New York Medical College Valhalla, NY, USA

III. Grants

Active

Title	Source	Position	Years
Phase I studies of LNA-i-miR 221 and LNA Gapmer 17-92 inhibitor in refractory multiple myeloma patients (n. 9980)	AIRC	PI	2016 → 2017
Immunotherapy of Human Cancer: microRNA-based immunotherapeutic strategies for Multiple Myeloma and Chronic Lymphocytic Leukemia (n. 16695)	AIRC CaRiCal Foundation	PI	2015 → 2018

Past Founding

A Research Platform for miRNA-based Treatment of Multiple Myeloma and Chronic Lymphocytic Leukemia, "Special Program Molecular Clinical Oncology - 5 per mille" n. 9980, 2010/15	AIRC	PI	2010 → 2015
Liposomal zoledronic acid in the treatment of multiple myeloma: preclinical models based on recapitulation of the bone marrow microenvironment. (n. 2009EHW394_003)	MIUR	Group Leader	2011 → 2013
Bone marrow microenvironment as a modulator of the sensitivity of multiple myeloma to targeted therapy- (Project Code: 5273	AIRC	PI	2007 → 2009
Microambiente tumorale e terapia a target molecolare: veicolazione selettiva di agenti antitumorali basata su silice mesoporosa	MIUR	PI	2008 → 2010

IV. Patents

Title	Reference	Year
Anti-myeloma activity of miR-125 mimics	10201500015888	2015
Anti-tumor activity of cluster miR-17-92 inhibitors for the treatment of multiple myeloma and other malignancies	RM2014A000712	2015
LNA-miR-221 inhibitors for the treatment of human cancer	RM2015A000150	2015
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle	RM2013A000635	2013
miR-221/222 inhibitors for the treatment of multiple myeloma	PCT/IB2013050328	2013
SNALPS formulation for entrapment of miR-34a for the treatment of multiple myeloma	FI2012A000025	2012
Self-assembling nanoparticles for the treatment of human cancer	11776382.1	2011
Three Dimensional polymeric scaffold (for in vivo recapitulation of the human bone marrow microenvironment)	RM2010A000454	2011
Zoledronic acid formulations for the treatment of multiple myeloma	FI2009A000190	2009

V. Cancer Societies

Active member, American Association for Cancer Research (AACR)

Active member, Associazione Italiana di Oncologia Medica (AIOM)

Fellowships

2001→2002 International fellowship AIRC

1990→1991 National fellowship, Bio-oncology Consortium, Bari, Italy

Experience in GCP trials as PI since 2002

I authorize the processing of personal data.

Prof. Pierfrancesco Tassone

Catanzaro, Jul 26 2019

Publications
[\(http://publicationslist.org/tassone\)](http://publicationslist.org/tassone)

1. Juli G, Oliverio M, Bellizzi D, Gallo Cantafio ME, Grillone K, Passarino G, Colica C, Nardi M, Rossi M, Procopio A, Tagliaferri P, **Tassone P**, Amodio N. Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma. *Cancers (Basel)*. 2019 Jul 16;11(7). pii: E990. doi: 10.3390/cancers11070990
2. Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, **Tassone P**, Tagliaferri P, Correale P. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. *Mol Clin Oncol*. 2019 Jul;11(1):81-90. doi: 10.3892/mco.2019.1859. Epub 2019 May 16.
3. Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, **Tassone P**, Botta C. Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. *J HematolOncol*. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.
4. Misso G, Zarone MR, Lombardi A, Grimaldi A, Cossu AM, Ferri C, Russo M, Vuoso DC, Luce A, Kawasaki H, Di Martino MT, Virgilio A, Festa A, Galeone A, De Rosa G, Irace C, Donadelli M, Necas A, Amler E, Tagliaferri P, **Tassone P**, Caraglia M. miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. *Mol Ther Nucleic Acids*. 2019 Jun 7;16:391-406. doi: 10.1016/j.omtn.2019.02.023. Epub 2019 Mar 13.
5. Olivito F, Amodio N, Di Gioia ML, Nardi M, Oliverio M, Juli G, Tassone P, Procopio A. Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. *Medchemcomm*. 2018 Dec 5;10(1):116-119. doi: 10.1039/c8md00503f. eCollection 2019 Jan 1.
6. Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3. Review.
7. Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, **Tassone P**. Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. *Cancers (Basel)*. 2019 Feb 18;11(2). pii: E236. doi: 10.3390/cancers11020236.
8. Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, **Tassone P**, Tagliaferri P. Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study. *Clin Pharmacol Ther*. 2019 Feb 10. doi: 10.1002/cpt.1391.
9. Taiana E, Ronchetti D, Favasuli V, Todoerti K, Manzoni M, Amodio N, **Tassone P**, Agnelli L, Neri A. Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. *Haematologica*. 2018 Sep 13. pii: haematol.2018.201301. doi: 10.3324/haematol.2018.201301.
10. Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, **Tassone P**. The potential role of miRNAs in multiple myeloma therapy. *Expert Rev Hematol*. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041.

11. Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, **Tassone P**. miR-22 suppresses DNA ligase III addiction in multiple myeloma. Leukemia. 2018 Aug 17. doi: 10.1038/s41375-018-0238-2
12. Bryant LM, Daniels KE, Cognetti DM, **Tassone P**, Luginbuhl AJ, Curry JM. Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients. Laryngoscope Investig Otolaryngol. 2018 Apr 16;3(3):169-177. doi: 10.1002/lio2.154. eCollection 2018 Jun. Review.
13. **Tassone P**, Savard C, Topf MC, Keane W, Luginbuhl A, Curry J, Cognetti D. Association of Positive Initial Margins With Survival Among Patients With Squamous Cell Carcinoma Treated With Total Laryngectomy. JAMA Otolaryngol Head Neck Surg. 2018 Nov 1;144(11):1030-1036. doi: 10.1001/jamaoto.2018.1095.
14. Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, **Tassone P**. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601.
15. Raimondi L, De Luca A, Giavaresi G, Barone A, Tagliaferri P, **Tassone P**, Amodio N. Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. Curr Med Chem. 2018 Jun 29. doi: 10.2174/0929867325666180629153141.
16. Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, **Tassone P**, Pirtoli L, Cusi MG, Tagliaferri P. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17.
17. Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, **Tassone P**. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol. 2018 May 8;11(1):63. doi: 10.1186/s13045-018-0606-4. Review.
18. Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, **Tassone P**. Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget. 2018 Apr 13;9(28):20119-20133. doi: 10.18632/oncotarget.24614. eCollection 2018 Apr 13. Review.
19. Santolla MF, Lappano R, Cirillo F, Rigitaccioli DC, Sebastiani A, Abonante S, **Tassone P**, Tagliaferri P, Di Martino MT, Maggiolini M, Vivacqua A. miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. J Exp Clin Cancer Res. 2018 May 2;37(1):94. doi: 10.1186/s13046-018-0767-6.
20. Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, **Tassone P**, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969.
21. Bryant LM, **Tassone P**, Curry J, Luginbuhl A, Cognetti D. Buccal space malignancy in the setting of chronic sialadenitis: A report of 2 cases. Ear Nose Throat J. 2018 Jan-Feb;97(1-2):E12-E14.
22. Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, **Tassone P**. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of

- proteasome subunits and triggers anti-multiple myeloma activity. *Leukemia*. 2018 Sep;32(9):1948-1957. doi: 10.1038/s41375-018-0067-3.
23. Botta C, Ciliberto D, Rossi M, Staropoli N, Cucè M, Galeano T, Tagliaferri P, **Tassone P**. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. *Blood Adv*. 2017 Feb 27;1(7):455-466. doi: 10.1182/bloodadvances.2016003905. eCollection 2017 Feb 28.
24. Stamato MA, Juli G, Romeo E, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, **Tassone P**, Amodio N. Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. *Oncotarget*. 2017 Nov 20;8(63):106527-106537. doi: 10.1863/oncotarget.22507. eCollection 2017 Dec 5.
25. Franzoni S, Vezzelli A, Turtoro A, Solazzo L, Greco A, **Tassone P**, Di Martino MT, Breda M. Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS. *J Pharm Biomed Anal*. 2018 Feb 20;150:300-307. doi: 10.1016/j.jpba.2017.12.027.
26. Zarone MR, Misso G, Grimaldi A, Zappavigna S, Russo M, Amler E, Di Martino MT, Amodio N, Tagliaferri P, **Tassone P**, Caraglia M. Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. *Sci Rep*. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.
27. Raimondi L, De Luca A, Costa V, Amodio N, Carina V, Bellavia D, **Tassone P**, Pagani S, Fini M, Alessandro R, Giavaresi G. Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. *Oncotarget*. 2017 Aug 3;8(59):100831-100851. doi: 10.1863/oncotarget.19852. eCollection 2017 Nov 21. Review.
28. Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, **Tassone P**, Tagliaferri P, Cusi MG, Pirtoli L, Correale P. Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSCLC patients. *J Thorac Dis*. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68.
29. Gullà A, Hidemitsu T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, **Tassone P**, Anderson KC. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. *Leukemia*. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21.
30. Botta C, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, **Tassone P**. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. *Leukemia*. 2018 Apr;32(4):1003-1015. doi: 10.1038/leu.2017.336. Epub 2017 Nov 21.
31. Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, **Tassone P**, Tagliaferri P, Pirtoli L, Correale P. Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEB). *Oncotarget*. 2017 Aug 24;8(44):75904-75913. doi: 10.1863/oncotarget.20411. eCollection 2017 Sep 29.
32. Botta C, Cuce M, Caracciolo D, Fiorillo L, Tagliaferri P, **Tassone P**. Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment. *Curr Cancer Drug Targets*. 2017;17(9):819-838. doi: 10.2174/1568009617666170330154756. Review.
33. Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, Emionite L, Fabris S, Recchia AG, Gentile M, Neumaier CE, Reverberi D, Massara R, Boccardo S, Basso L, Salvi S, Rosa F, Cilli M, Zupo S, Truini M, **Tassone P**, Calabrese M, Negrini M, Neri A, Morabito F, Fais F, Ferrarini M. Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic

- leukemia: implication for therapy. *Leukemia*. 2017 Sep;31(9):1894-1904. doi: 10.1038/leu.2016.394. Epub 2017 Jan 5.
34. Correale P, Botta C, Ciliberto D, Pastina P, Ingariola R, Zappavigna S, **Tassone P**, Pirtoli L, Caraglia M, Tagliaferri P. Immunotherapy of colorectal cancer: new perspectives after a long path. *Immunotherapy*. 2016 Nov;8(11):1281-1292. Review.
 35. Botta C, Di Martino MT, Ciliberto D, Cucè M, Correale P, Rossi M, Tagliaferri P, **Tassone P**. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. *Blood Cancer J*. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118.
 36. Amodio N, D'Aquila P, Passarino G, **Tassone P**, Bellizzi D. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. *Expert Opin Ther Targets*. 2017 Jan;21(1):91-101. Review.
 37. Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L, Sun C, Hu Y, Ball CR, Glimm H, Sattler M, Goldschmidt H, Wagner EF, **Tassone P**, Jaeger D, Podar K. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. *Leukemia*. 2017 Jul;31(7):1570-1581. doi: 10.1038/leu.2016.358.
 38. Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, **Tassone P**, Tagliaferri P, Del Vecchio MT, Pirtoli L, Correale P. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. *Cancer Biol Ther*. 2016 Nov;17(11):1213-1220.
 39. Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, Botta C, Pignata S, **Tassone P**, Tagliaferri P. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. *Oncotarget*. 2016 Dec 13;7(50):82741-82756. doi: 10.18632/oncotarget.12633. Review.
 40. Mimmi S, Vecchio E, Iaccino E, Rossi M, Lupia A, Albano F, Chiurazzi F, Fiume G, Pisano A, Ceglia S, Pontoriero M, Golino G, **Tassone P**, Quinto I, Scala G, Palmieri C. Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. *Leukemia*. 2016 Dec;30(12):2419-2422. doi: 10.1038/leu.2016.245. Epub 2016 Aug 29.
 41. Misso G, Zarone MR, Grimaldi A, Di Martino MT, Lombardi A, Kawasaki H, Stiuso P, **Tassone P**, Tagliaferri P, Caraglia M. Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment. *Curr Drug Targets*. 2017;18(1):35-55. Review
 42. Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, Botta C, Pignata S, **Tassone P**, Tagliaferri P. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. *Oncotarget*. 2016 Oct 13. doi: 10.18632/oncotarget.12633.
 43. Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, **Tassone P**, Tagliaferri P, Del Vecchio MT, Pirtoli L, Correale P. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. *Cancer Biol Ther*. 2016 Oct 28:0.
 44. Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, **Tassone P**, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. *Cell Death Discov*. 2016 Oct 3;2:16025.
 45. Agapito G, Botta C, Guzzi PH, Arbitrio M, Di Martino MT, **Tassone P**, Tagliaferri P, Cannataro M. OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes. *Microarrays (Basel)*. 2016 Sep 23;5(4).

46. Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, Matis S, Colombo M, Galletti S, Taiana E, Recchia AG, Bossio S, Gentile M, Musolino C, Di Raimondo F, Grilli A, Bicciato S, Cortelezzi A, **Tassone P**, Morabito F, Ferrarini M, Neri A. lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. *Blood Cancer J.* 2016 Sep 9;6(9):e468.
47. Botta C, Misso G, Martino EC, Pirtoli L, Cusi MG, **Tassone P**, Tagliaferri P, Caraglia M, Correale P. The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. *Cell Death Dis.* 2016 Jul 21;7:e2299.
48. Gallo Cantafio ME, Nielsen BS, Mignogna C, Arbitrio M, Botta C, Frandsen NM, Rolfo C, Tagliaferri P, **Tassone P**, Di Martino MT. Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates. *Mol Ther Nucleic Acids.* 2016 Jun 21;5(6). doi: 10.1038/mtna.2016.36.
49. Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, **Tassone P**, Tagliaferri P. DMETTM (Drug Metabolism Enzymes and Transporters): a Pharmacogenomic platform for precision medicine. *Oncotarget.* 2016 Jun 9.
50. Misso G, Zarone MR, Grimaldi A, Di Martino MT, Lombardi A, Kawasaki H, Stiuso P, **Tassone P**, Tagliaferri P, Caraglia M. Non Coding RNAs: a new avenue for the self-tailoring of blood cancer treatment. *Curr Drug Targets.* 2016 Jun 5.
51. Pinto C, Bella MA, Capoluongo E, Carrera P, Clemente C, Colombo N, Cortesi L, De Rosa G, Fenizia F, Genuardi M, Gori S, Guarneri V, Marchetti A, Marchetti P, Normanno N, Pasini B, Pignata S, Radice P, Ricevuto E, Russo A, Tagliaferri P, **Tassone P**, Truini M, Varesco L. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. *Future Oncol.* 2016 Sep;12(18):2071-5.
52. Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastrà C, Presta I, Malara N, Salvino A, **Tassone P**, Tagliaferri P, Barni T, Donato G, Di Vito A. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. *J Ovarian Res.* 2016 May 21;9(1):31. doi: 10.1186/s13048-016-0238-7.
53. Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, **Tassone P**. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. *Mol Cancer Ther.* 2016 Jun;15(6):1364-75.
54. Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, Gandolfo C, Carbone F, Baldari TC, **Tassone P**, Tagliaferri P, Pirtoli L, Cusi MG. Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. *Oncoimmunology.* 2015 Dec 21;5(4):e1101205.
55. Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, **Tassone P**. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. *Mol Cancer Ther.* 2016 Mar 28. pii: molcanther.0985.2015.
56. Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, **Tassone P**. Mir-221/222 are promising targets for innovative anticancer therapy. *Expert Opin Ther Targets.* 2016 Mar 21:1-10.
57. Rotundo MS, Galeano T, **Tassone P**, Tagliaferri P. mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. *Oncotarget.* 2016 Feb 17. doi:10.18632/oncotarget.7446.

58. Raimondi L, De Luca A, Morelli E, Giavaresi G, Tagliaferri P, **Tassone P**, Amodio N. MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. *Biomed Res Int.* 2016;2016:6504593. doi: 10.1155/2016/6504593. Epub 2016 Jan 4. Review.
59. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlerksen B, Chia SK, Mansi J, Barrios CH, Gnani M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, **Tassone P**, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2016 Mar;17(3):367-77. doi: 10.1016/S1470-2045(15)00551-3.
60. Ciliberto D, Staropoli N, Chiellino S, Botta C, **Tassone P**, Tagliaferri P. Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. *Pancreatology.* 2016 Mar-Apr;16(2):249-58. doi: 10.1016/j.pan.2016.01.003.
61. Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D'Aquila P, Bellizzi D, Passarino G, Adamia S, Neri A, Hunter ZR, Treon SP, Anderson KC, **Tassone P**, Munshi NC. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. *Blood Cancer J.* 2016 Jan 15;6:e380. doi: 10.1038/bcj.2015.106.
62. Rossi M, Tagliaferri P, **Tassone P**. MicroRNAs in multiple myeloma and related bone disease. *Ann Transl Med.* 2015 Dec;3(21):334. doi: 10.3978/j.issn.2305-5839.2015.12.13. Review.
63. Cosco D, Cilurzo F, Maiuolo J, Federico C, Di Martino MT, Cristiano MC, **Tassone P**, Fresta M, Paolino D. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. *Sci Rep.* 2015 Dec 1;5:17579. doi: 10.1038/srep17579. PubMed PMID: 26620594;
64. Arbitrio M, Di Martino MT, Barbieri V, Agapito G, Guzzi PH, Botta C, Iuliano E, Scionti F, Altomare E, Codispoti S, Conforti S, Cannataro M, **Tassone P**, Tagliaferri P. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis. *Cancer Chemother Pharmacol.* 2016 Jan;77(1):205-9. doi: 10.1007/s00280-015-2916-3. Epub 2015 Nov 25.
65. Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, **Tassone P**. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. *Clin Cancer Res.* 2016 Mar 1;22(5):1222-33. doi: 10.1158/1078-0432.CCR-15-0489. Epub 2015 Nov 2.
66. Calura E, Bisognin A, Manzoni M, Todoerti K, Taiana E, Sales G, Morgan GJ, Tonon G, Amodio N, **Tassone P**, Neri A, Agnelli L, Romualdi C, Bortoluzzi S. Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. *Oncotarget.* 2016 Jan 19;7(3):2367-78. doi: 10.18632/oncotarget.6151.
67. Lionetti M, Barbieri M, Todoerti K, Agnelli L, Fabris S, Tonon G, Segalla S, Cifola I, Pinatel E, **Tassone P**, Musto P, Baldini L, Neri A. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. *Oncotarget.* 2015 Sep 22;6(28):26129-41. doi: 10.18632/oncotarget.4674. PubMed PMID: 26305418; PubMed Central PMCID: PMC4694891.
68. Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, **Tassone P**. Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.

Oncotarget. 2015 Jun 24.

69. Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S, De Angelis AM, Mendicino F, Botta C, Caraglia M, **Tassone P**, Tagliaferri P. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? *Cancer Biol Ther.* 2015 Jun 10:1-12.
70. Di Martino MT, Guzzi PH, Caracciolo D, Agnelli L, Neri A, Walker BA, Morgan GJ, Cannataro M, **Tassone P**, Tagliaferri P. Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. *Oncotarget.* 2015 May 27
71. Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, **Tassone P**, Tagliaferri P, Pirtoli L, Correale P. Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. *Cancer Immunol Immunother.* 2015 Jun 2.
72. Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, **Tassone P**, Marto JA, Anderson KC, Carrasco RD. The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. *Nature Med.* 2015 Jun;21(6):572-580.
73. Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, Gullà A, Foresta U, Rita Pitari M, Botta C, Rossi M, Neri A, Munshi NC, Anderson KC, Tagliaferri P, **Tassone P**. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. *Leukemia.* 2015 May 19.
74. Di Martino MT, Amodio N, **Tassone P**, Tagliaferri P. Functional Analysis of microRNA in Multiple Myeloma. *Methods Mol Biol.* 2015 May 14.
75. Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, **Tassone P**. miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. *Oncotarget.* 2015 Apr 12.
76. Raimondi L, De Luca A, Amodio N, Manno M, Raccosta S, Taverna S, Bellavia D, Naselli F, Fontana S, Schillaci O, Giardino R, Fini M, **Tassone P**, Santoro A, De Leo G, Giavaresi G, Alessandro R. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. *Oncotarget.* 2015 Apr 12.
77. Maura F, Cutrona G, Mosca L, Matis S, Lionetti M, Fabris S, Agnelli L, Colombo M, Massucco C, Ferracin M, Zagatti B, Reverberi D, Gentile M, Recchia AG, Bossio S, Rossi D, Gaidano G, Molica S, Cortelezzi A, Di Raimondo F, Negri M, **Tassone P**, Morabito F, Ferrarini M, Neri A. Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. *Leuk Lymphoma.* 2015 Apr 10:1-51.
78. Botta C, Gullà A, Correale P, Tagliaferri P, **Tassone P**. Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. *Front Oncol.* 2014 Dec 8;4:348.
79. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, **Tassone P**, Caraglia M. Mir-34: a new weapon against cancer? *Mol Ther Nucleic Acids.* 2014 Sep 23;3:e194.

80. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldès C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med.* 2014 Sep 4;371(10):906-17.
81. Kang YK, Rha SY, **Tassone P**, Barriuso J, Yu R, Szado T, Garg A, Bang YJ. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. *Br J Cancer.* 2014 Aug 12;111(4):660-6.
82. Negrini M, Cutrona G, Bassi C, Fabris S, Zagatti B, Colombo M, Ferracin M, D'Abundo L, Saccetti E, Matis S, Lionetti M, Agnelli L, Gentile M, Recchia AG, Bossio S, Reverberi D, Rigolin G, Calin GA, Sabbioni S, Russo G, **Tassone P**, Morabito F, Ferrarini M, Neri A. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. *Clin Cancer Res.* 2014 Aug 1;20(15):4141-53.
83. Cosco D, Federico C, Maiuolo J, Bulotta S, Molinaro R, Paolino D, **Tassone P**, Fresta M. Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes. *Int J Nanomedicine.* 2014 May 15;9:2359-72.
84. Rossi M, Amodio N, Di Martino MT, Tagliaferri P, **Tassone P**, Cho WC. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. *Curr Pharm Biotechnol.* 2014;15(5):459-67.
85. Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, Caracciolo D, Gullà A, Neri A, Taverna S, D'Aquila P, Alessandro R, Giordano A, Tagliaferri P, **Tassone P**. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. *Oncotarget.* 2014 May 30;5(10):3039-54.
86. Leotta M, Biamonte L, Raimondi L, Ronchetti D, Di Martino MT, Botta C, Leone E, Pitari MR, Neri A, Giordano A, Tagliaferri P, **Tassone P**, Amodio N. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. *J Cell Physiol.* 2014 Dec;229(12):2106-16.
87. Tuccillo FM, de Laurentiis A, Palmieri C, Fiume G, Bonelli P, Borrelli A, **Tassone P**, Scala I, Buonaguro FM, Quinto I, Scala G. Aberrant glycosylation as biomarker for cancer: focus on CD43. *Biomed Res Int.* 2014;2014:742831.
88. Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gullà A, Gallo Cantafio ME, Misso G, Tagliaferri P, **Tassone P**, Caraglia M, De Rosa G. Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. *Biomed Res Int.* 2014;2014:217365.
89. Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, **Tassone P**, Tagliaferri P. Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. *Cancer Biol Ther.* 2014 Jun 1;15(6):707-20.
90. Fulciniti M, Amodio N, Bandi RL, Munshi M, Yang G, Xu L, Hunter Z, **Tassone P**, Anderson KC, Treon SP, Munshi NC. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. *Blood.* 2014 Apr 24;123(17):2673-81.

91. Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, Franco R, Lusa S, Cannataro M, Tagliaferri P, De Rosa G, **Tassone P**, Caraglia M. In vivo activity of miR-34° mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. *PLoS One*. 2014 Feb 27;9(2):e90005.
92. Di Martino MT, Gullà A, Gallo Cantafio ME, Altomare E, Amadio N, Leone E, Morelli E, Lio SG, Caracciolo D, Rossi M, Frandsen NM, Tagliaferri P, **Tassone P**. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. *PLoS One*. 2014 Feb 21;9(2):e89659.
93. Rossi M, Gentile M, Toscano R, Recchia AG, Bossio S, Caruso N, De Stefano L, Granata T, Pellicanò M, Vigna E, Tagliaferri P, **Tassone P**, Morabito F. Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia. *Leuk Lymphoma*. 2014 Jun;55(6):1394-6.
94. Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, **Tassone P**, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P. Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients: The GOLFIG-2 Multicentric Open-label Randomized Phase III Trial. *J Immunother*. 2014 Jan;37(1):26-35.
95. Amadio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, Leone E, Passarino G, Neri A, Giordano A, Tagliaferri P, **Tassone P**. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. *Cell Cycle*. 2013 Sep 25;12(23).
96. Morabito F, Mosca L, Cutrona G, Agnelli L, Tuana G, Ferracin M, Zagatti B, Lionetti M, Fabris S, Maura F, Matis S, Gentile M, Vigna E, Colombo M, Massucco C, Recchia AG, Bossio S, De Stefano L, Ilariucci F, Musolino C, Molica S, Di Raimondo F, Cortelezzi A, **Tassone P**, Negrini M, Monti S, Rossi D, Gaidano G, Ferrarini M, Neri A. Clinical Monoclonal B lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: a Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. *Clin Cancer Res*. 2013 Sep 13.
97. Ronchetti D, Mosca L, Cutrona G, Tuana G, Gentile M, Fabris S, Agnelli L, Ciceri G, Matis S, Massucco C, Colombo M, Reverberi D, Recchia AG, Bossio S, Negrini M, **Tassone P**, Morabito F, Ferrarini M, Neri A. Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. *BMC Med Genomics*. 2013 Sep 3;6(1):27.
98. Rossi M, Gentile M, Toscano R, Recchia AG, Bossio S, Caruso N, De Stefano L, Granata T, Pellicanò M, Vigna E, Tagliaferri P, **Tassone P**, Morabito F. Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients. *Leuk Lymphoma*. 2013 Sep 2.
99. Rossi M, Amadio N, Di Martino MT, Caracciolo D, Tagliaferri P, **Tassone P**. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. *Curr Drug Targets*. 2013 Sep;14(10):1144-9.
100. Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, **Tassone P**, Tagliaferri P, Correale P. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. *Cancer Biol Ther*. 2013 Jun;14(6):469-75.
101. Misso G, Zappavigna S, Castellano M, De Rosa G, Di Martino MT, Tagliaferri P, **Tassone P**, Caraglia M. Emerging pathways as individualized therapeutic target of multiple myeloma.

102. Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, Grimaldi A, Luce A, **Tassone P**, Caraglia M, Tagliaferri P. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? *J Drug Deliv.* 2013;2013:905091.
103. Rossi M, Botta C, Correale P, **Tassone P**, Tagliaferri P. Immunologic microenvironment and personalized treatment in multiple myeloma. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S83-93.
104. Amodio N, Di Martino MT, Neri A, **Tagliaferri P**, Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S125-37.
105. Agnelli L, Tassone P, Neri A. Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S55-68.
106. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omede' P, Morabito F, **Tassone P**, Boccadoro M, Palumbo A, Neri A. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. *Clin Cancer Res.* 2013 Jun 15;19(12):3130-42.
107. Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, Lombardi L, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, A, Omede' P, **Tassone P**, Boccadoro M, Palumbo A, Neri A, Musto P, Falcone Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. *Clin Cancer Res.* 2013 Jun 15;19(12):3247-58.
108. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, **Tassone P**. Targeting miR-21 inhibits in vitro and in vivo myeloma cell growth. *Clin Cancer Res.* 2013.
109. Di Martino MT, Gullà A, Gallo Cantafio E, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, **Tassone P**. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. *Oncotarget* 2013.
110. Staropoli N, Ciliberto D, Botta C, Fiorillo L, Gualtieri S, Salvino A, **Tassone P**, Tagliaferri P. Pegylated liposomal doxorubicin in ovarian cancer treatment: A mono-institutional retrospective analysis. Do we still need it? *J Ovarian Res.* 2013 Feb 6;6(1):10.
111. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, Caraglia M, Ferrarini M, Giordano A, Tagliaferri P, **Tassone P**. miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease. *J Cell Physiol.* 2012 Dec 18.
112. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, Gullà AM, Pitari MR, Conforti F, Rossi M, Agosti V, Fulciniti M, Misso G, Morabito F, Ferrarini M, Neri A, Caraglia M, Munshi NC, Anderson KC, Tagliaferri P, **Tassone P**. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.

Cell Death Dis. 2012 Nov 29;3:e436.

113. Ronchetti D, Todoerti K, Tuana G, Agnelli L, Mosca L, Lionetti M, Fabris S, Colapietro P, Miozzo M, Ferrarini M, **Tassone P**, Neri A. The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. *Blood Cancer J.* 2012 Nov 23;2:e96.
114. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, **Tassone P**. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. *Oncotarget.* 2012 Oct;3(10):1246-58.
115. Guzzi PH, Agapito G, Di Martino MT, Arbitrio M, Tassone P, Tagliaferri P, Cannataro M. DMET-analyzer: automatic analysis of Affymetrix DMET data. *BMC Bioinformatics.* 2012 Oct 5;13:258.
116. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, **Tassone P**. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. *Clin Cancer Res.* 2012 Nov 15;18(22):6260-70.
117. Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, **Tassone P**, Tagliaferri P. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. *Eur J Cancer.* 2013 Feb;49(3):593-603.
118. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, **Tassone P**, Anderson KC, Munshi NC. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. *Blood.* 2012 Dec 13;120(25):5002-13.
119. Correale P, Rotundo MS, Botta C, Del Vecchio MT, **Tassone P**, Tagliaferri P. Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. *Oncoimmunology.* 2012 Jul 1;1(4):531-532.
120. Lionetti M, Agnelli L, Lombardi L, **Tassone P**, Neri A. MicroRNAs in the pathobiology of multiple myeloma. *Curr Cancer Drug Targets.* 2012 Sep;12(7):823-37.
121. **Tassone P**, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M, Tagliaferri P. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. *Curr Cancer Drug Targets.* 2012 Sep;12(7):814-22.
122. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, **Tassone P**. Promises and challenges of MicroRNA-based treatment of multiple myeloma. *Curr Cancer Drug Targets.* 2012 Sep;12(7):838-46.
123. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, Misso G, **Tassone P**, Caraglia M. Molecular targets for the treatment of multiple myeloma. *Curr Cancer Drug Targets.* 2012 Sep;12(7):757-67.
124. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, **Tassone P**, Tagliaferri P, Correale P. Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. *J Immunother.* 2012 Jun;35(5):440-7.

125. Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, **Tassone P**, Tagliaferri P. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. *Oncol Rep.* 2012 Jun;27(6):1849-56.
126. Pal J, Fulciniti M, Nanjappa P, Buon L, Tai YT, **Tassone P**, Munshi NC, Shammas MA. Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. *Cancer Genomics Proteomics.* 2012 Mar-Apr;9(2):55-66.
127. Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A, Ave E, Zaffino F, Di Maira G, Ruzzene M, Adami F, Zambello R, Pitari MR, **Tassone P**, Pinna LA, Gurrieri C, Semenzato G, Piazza F. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. *Clin Cancer Res.* 2012 Apr 1;18(7):1888-900.
128. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, **Tassone P**, Tagliaferri P. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. *Clin Cancer Res.* 2012 Feb 1;18(3):850-7.
129. Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, **Tassone P**, Mansoor A, Stewart DA, Lonial S, Boise LH, Bahlis NJ. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. *Blood.* 2011 Dec 8;118(24):6368-79.
130. Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, **Tassone P**, Tagliaferri P. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. *Cancer Biol Ther.* 2011 Nov 1;12(9):780-7.
131. Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C, Minvielle S, Tai YT, **Tassone P**, Avet-Loiseau H, Hideshima T, Anderson KC, Munshi NC. Significant biological role of sp1 transactivation in multiple myeloma. *Clin Cancer Res.* 2011 Oct 15;17(20):6500-9.
132. Di Martino MT, Arbitrio M, Guzzi PH, Leone E, Baudi F, Piro E, Prantera T, Cucinotto I, Calimeri T, Rossi M, Veltri P, Cannataro M, Tagliaferri P, **Tassone P**. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. *Br J Haematol.* 2011 Aug;154(4):529-33.
133. Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin C, Duggan P, **Tassone P**, Mansoor A, Stewart DA, Boise LH, Ghobrial IM, Bahlis NJ. Integrin β 7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. *Blood.* 2011 Jun 9;117(23):6202-13.
134. Marra M, Salzano G, Leonetti C, **Tassone P**, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. *Nanomedicine.* 2011 Dec;7(6):955-64.
135. de Laurentiis A, Gaspari M, Palmieri C, Falcone C, Iaccino E, Fiume G, Massa O, Masullo M, Tuccillo FM, Roveda L, Prati U, Fierro O, Cozzolino I, Troncone G, **Tassone P**, Scala G, Quinto

- I. Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein.
Mol Cell Proteomics. 2011 May;10(5):M111.007898.
136. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, Foresta U, Piro E, Ferrara F, Amorosi A, Bahlis N, Anderson KC, Munshi N, Tagliaferri P, Causa F, **Tassone P**. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.
Leukemia. 2011 Apr;25(4):707-11.
137. Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, **Tassone P**, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Cancer Biol Ther. 2010 May 1;9(9):685-93.
138. Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, **Tassone P**, Abbruzzese A, Tagliaferri P, Caraglia M. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Eur J Cancer. 2010 Jun;46(9):1703-11.
139. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L, **Tassone P**, Francini G, Tagliaferri P. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
J Immunother. 2010 May;33(4):435-41.
140. **Tassone P**, Tagliaferri P, Rossi M, Calimeri T, Bulotta A, Abbruzzese A, Caraglia M, Neri P. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.
Curr Cancer Drug Targets. 2009 Nov;9(7):854-70. Review.
141. Marra M, Abbruzzese A, Addeo R, Del Prete S, **Tassone P**, Tonini G, Tagliaferri P, Santini D, Caraglia M. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.
Curr Cancer Drug Targets. 2009 Nov;9(7):791-800.
142. Fulciniti M, Hideshima T, Vermot-Droz C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith ES, Wang W, Prabhala R, Tai YT, **Tassone P**, Anderson KC, Munshi NC. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
143. Tagliaferri P, Ventura M, Baudi F, Cucinotto I, Arbitrio M, Di Martino MT, **Tassone P**. BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
J Ovarian Res. 2009 Oct 13;2:14.
144. Blotta S, **Tassone P**, Prabhala RH, Tagliaferri P, Cervi D, Amin S, Jakubikova J, Tai YT, Podar K, Mitsiades CS, Zullo A, Franco B, Anderson KC, Munshi NC. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
Blood. 2009 Oct 8;114(15):3276-84.
145. Fulciniti M, **Tassone P**, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
Blood. 2009 Jul 9;114(2):371-9.

146. **Tassone P**, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M, Tagliaferri P. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. *Cancer Biol Ther.* 2009 Apr;8(7):648-53.
147. Cosco D, Bulotta A, Ventura M, Celia C, Calimeri T, Perri G, Paolino D, Costa N, Neri P, Tagliaferri P, **Tassone P**, Fresta M. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. *Cancer Chemother Pharmacol.* 2009 Oct;64(5):1009-20.
148. Burger R, Le Gouill S, Tai YT, Shringarpure R, **Tassone P**, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, Caulder E, Neilan CL, Vaddi K, Li J, Gramatzki M, Fridman JS, Anderson KC. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. *Mol Cancer Ther.* 2009 Jan;8(1):26-35.
149. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Visconti C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, **Tassone P**. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. *Br J Haematol.* 2008 Nov;143(4):520-31.
150. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, **Tassone P**, Francini G. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). *Clin Cancer Res.* 2008 Jul 1;14(13):4192-9.
151. Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, Gnoni A, Di Renzo N, Dammacco F, **Tassone P**, Ribatti D, Gambacorti-Passerini C, Vacca A. Validation of PDGFR β and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. *Blood.* 2008 Aug 15;112(4):1346-56.
152. Neri A, Marmiroli S, **Tassone P**, Lombardi L, Nobili L, Verdelli D, Civallero M, Cosenza M, Bertacchini J, Federico M, De Pol A, Deliliers GL, Sacchi S. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. *Leuk Lymphoma.* 2008 Jul;49(7):1374-83.
153. Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, **Tassone P**, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. *Leukemia.* 2008 Jul;22(7):1410-8.
154. Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, **Tassone P**, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. *Br J Haematol.* 2008 May;141(5):598-606.
155. Barbieri V, **Tassone P**, Tagliaferri P. The IASLC Lung Cancer Staging Project: revision proposal of pleural effusion and contralateral nodule staging. *J Thorac Oncol.* 2008 Mar;3(3):317; author reply 317-8.
156. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, **Tassone P**, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. *Clin Cancer Res.* 2007 Oct 1;13(19):5903-9.

157. Neri P, **Tassone P**, Shammas M, Yasui H, Schipani E, Batchu RB, Blotta S, Prabhala R, Catley L, Hamasaki M, Hideshima T, Chauhan D, Jacob GS, Picker D, Venuta S, Anderson KC, Munshi NC. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia. 2007 Dec;21(12):2519-26. Epub 2007 Sep 20.
158. Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, **Tassone P**, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep;35(9):1366-75.
159. Caraglia M, Marra M, Visconti C, D'Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, **Tassone P**, Venuta S, Abbruzzese A, Tagliaferri P. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. Int J Cancer. 2007 Nov 15;121(10):2317-30.
160. Catley L, Hideshima T, Chauhan D, Neri P, **Tassone P**, Bronson R, Song W, Tai YT, Munshi NC, Anderson KC. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol. 2007 Jul;35(7):1038-46.
161. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, **Tassone P**, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 1;110(5):1656-63.
162. **Tassone P**, Tagliaferri P, Cucinotto I, Lavecchia AM, Leone F, Pietragalla A, Salvino A, Barbieri V, Venuta S. Pegylated liposomal doxorubicin is active in Stewart-Treves syndrome. Ann Oncol. 2007 May;18(5):959-60.
163. **Tassone P**, Tagliaferri P, Fulciniti MT, Di Martino MT, Venuta S. Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues. Curr Pharm Des. 2007;13(5):487-96.
164. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, **Tassone P**, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 1;109(3):1220-7.
165. Hideshima T, Neri P, **Tassone P**, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 1;12(19):5887-94.
166. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, **Tassone P**, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul;134(2):145-56.
167. **Tassone P**, Tagliaferri P, Rossi M, Gaspari M, Terracciano R, Venuta S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur J Cancer. 2006 Jul;42(11):1530-8.

168. Neri P, Yasui H, Hidemitsu T, **Tassone P**, Raje N, Catley LP, Ishitsuka K, Blotta S, Kiziltepe T, Ocio EM, Fulciniti M, Kanekal S, Elliott GT, Munshi NC, Anderson KC. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. *Br J Haematol.* 2006 Jul;134(1):37-44.
169. Chatterjee M, Chakraborty T, **Tassone P**. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. *Eur J Cancer.* 2006 Jul;42(11):1640-52.
170. Caraglia M, **Tassone P**, Marra M, Budillon A, Venuta S, Tagliaferri P. Targeting Raf-kinase: molecular rationales and translational issues. *Ann Oncol.* 2006 Jun;17 Suppl 7:vii124-7.
171. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hidemitsu T, Neri P, **Tassone P**, Atadja P, Chauhan D, Munshi NC, Anderson KC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. *Blood.* 2006 Nov 15;108(10):3441-9.
172. de Laurentiis A, Caterino M, Orrù S, Ruoppolo M, Tuccillo F, Masullo M, Quinto I, Scala G, Pucci P, Palmieri C, **Tassone P**, Salvatore F, Venuta S. Partial purification and MALDI-TOF MS analysis of UN1, a tumor antigen membrane glycoprotein. *Int J Biol Macromol.* 2006 Aug 15;39(1-3):122-6.
173. Prabhala RH, Neri P, Bae JE, **Tassone P**, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC. Dysfunctional T regulatory cells in multiple myeloma. *Blood.* 2006 Jan 1;107(1):301-4.
174. **Tassone P**, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. *Clin Cancer Res.* 2005 Jun 1;11(11):4251-8.
175. **Tassone P**, Neri P, Kutok JL, Tournilhac O, Santos DD, Hatjiharissi E, Munshi V, Venuta S, Anderson KC, Treon SP, Munshi NC. A SCID-hu in vivo model of human Waldenström macroglobulinemia. *Blood.* 2005 Aug 15;106(4):1341-5. Epub 2005 May
176. Tagliaferri P, **Tassone P**, Blotta S, Visconti C, Grillone F, Budillon A, Caraglia M, Venuta S. Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways. *Curr Drug Targets.* 2005 May;6(3):289-300.
177. **Tassone P**, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Shammas MA, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC. A clinically relevant SCID-hu in vivo model of human multiple myeloma. *Blood.* 2005 Jul 15;106(2):713-6.
178. **Tassone P**, Blotta S, Palmieri C, Masciari S, Quaresima B, Montagna M, D'Andrea E, Eramo OP, Migale L, Costanzo F, Tagliaferri P, Venuta S. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. *Int J Oncol.* 2005 May;26(5):1257-63.
179. Yasui H, Hidemitsu T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, **Tassone P**, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

Blood. 2005 Jul 15;106(2):706-12.

180. Hamasaki M, Hidemitsu T, **Tassone P**, Neri P, Ishitsuka K, Yasui H, Shiraishi N, Raje N, Kumar S, Picker DH, Jacob GS, Richardson PG, Munshi NC, Anderson KC. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Blood. 2005 Jun 1;105(11):4470-6.
181. Tagliaferri P, Caraglia M, Budillon A, Marra M, Vitale G, Visconti C, Masciari S, **Tassone P**, Abbruzzese A, Venuta S. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.
Cancer Immunol Immunother. 2005 Jan;54(1):1-10.
182. Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K, **Tassone P**, Chauhan D, Hidemitsu T, Denis L, Richardson P, Munshi NC, Anderson KC. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH₂-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Cancer Res. 2004 Dec 1;64(23):8746-53.
183. Goel A, Arnold CN, **Tassone P**, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnoli MM, Boland CR. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.
Int J Cancer. 2004 Dec 10;112(5):754-9.
184. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L, **Tassone P**, Rotoli B, Venuta S. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
Blood. 2005 Jan 1;105(1):251-8.
185. **Tassone P**, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hidemitsu T, Shringarpure R, Shi J, Allam CK, Wijdenes J, Venuta S, Munshi NC, Anderson KC. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Blood. 2004 Dec 1;104(12):3688-96.
186. Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Visconti C, Colao A, Prete SD, Tagliaferri P, **Tassone P**, Budillon A, Venuta S, Abbruzzese A. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
Oncogene. 2004 Sep 9;23(41):6900-13.
187. **Tassone P**, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, Munshi NC. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercaptopropyl)-maytansine against CD56+ multiple myeloma cells.
Cancer Res. 2004 Jul 1;64(13):4629-36.
188. Turco MC, Romano MF, Petrella A, Bisogni R, **Tassone P**, Venuta S. NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors.
Leukemia. 2004 Jan;18(1):11-7.
189. Caraglia M, Marra M, Giuberti G, D'Alessandro AM, Baldi A, **Tassone P**, Venuta S, Tagliaferri P, Abbruzzese A. The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells.
J Biochem. 2003 Jun;133(6):757-65.
190. **Tassone P**, Tagliaferri P, Visconti C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR, Venuta S. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.
Br J Cancer. 2003 Jun 16;88(12):1971-8.

191. **Tassone P**, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. *Br J Cancer.* 2003 Apr 22;88(8):1285-91.
192. Quaresima B, Alifano P, **Tassone P**, Avvedimento EV, Costanzo FS, Venuta S. Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with *Escherichia coli* MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function. *Biochem J.* 2003 Apr 1;371(Pt 1):183-9.
193. Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, Pepe S, Vitale G, Improta S, **Tassone P**, Venuta S, Bianco AR, Abbruzzese A. EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to interact interferon-alpha-mediated apoptosis in epidermoid cancer cells. *Cell Death Differ.* 2003 Feb;10(2):218-29.
194. **Tassone P**, Galea E, Forciniti S, Tagliaferri P, Venuta S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. *Int J Oncol.* 2002 Oct;21(4):867-73.
195. **Tassone P**, Bonelli P, Tuccillo F, Bond HM, D'Armiento FP, Galea E, Palmieri C, Tagliaferri P, Natali PG, Venuta S. Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas. *Anticancer Res.* 2002 Jul-Aug;22(4):2333-40.
196. **Tassone P**, Tagliaferri P, Galea E, Palmieri C, Bonelli P, Martelli ML, Tuccillo F, Turco MC, Venuta S. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. *Eur J Cancer.* 2002 May;38(8):1141-7.
197. **Tassone P**, Tuccillo F, Bonelli P, D'Armiento FP, Bond HM, Palmieri C, Tagliaferri P, Venuta S. Fetal ontogeny and tumor expression of the early thymic antigen UN1. *Int J Oncol.* 2002 Apr;20(4):707-11.
198. Baudi F, Quaresima B, Grandinetti C, Cuda G, Faniello C, **Tassone P**, Barbieri V, Bisegna R, Ricevuto E, Conforti S, Viel A, Marchetti P, Ficarella C, Radice P, Costanzo F, Venuta S. Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. *Hum Mutat.* 2001 Aug;18(2):163-4.
199. Cuda G, Gallelli A, Nisticò A, **Tassone P**, Barbieri V, Tagliaferri PS, Costanzo FS, Tranfa CM, Venuta S. Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients: a tool for early diagnosis? *Lung Cancer.* 2000 Dec;30(3):211-4.
200. Romano MF, Lamberti A, Bisogni R, **Tassone P**, Pagnini D, Storti G, Del Vecchio L, Turco MC, Venuta S. Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides. *Gene Ther.* 2000 Jul;7(14):1234-7.
201. **Tassone P**, Forciniti S, Galea E, Savino R, Turco MC, Iacopino P, Tagliaferri P, Morrone G, Ciliberto G, Venuta S. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. *Cell Death Differ.* 2000 Mar;7(3):327-8.

202. **Tassone P**, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P, Venuta S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. *Leukemia*. 2000 May;14(5):841-4.
203. Quaresima B, Grandinetti C, Baudi F, Tassone P, Barbieri V, Conforti S, Avvedimento EV, Costanzo F, Venuta S. Hereditary nonpolyposis colorectal cancer: identification of novel germline mutations in two kindreds not fulfilling the Amsterdam criteria. *Mutations in brief no. 203*. Online. *Hum Mutat*. 1998;12(6):433.
204. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, **Tassone P**, Turco MC, Venuta S. Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors. *Blood*. 1999 Dec 15;94(12):4060-6.
205. **Tassone P**, Tuccillo F, Bonelli P, Turco MC, Cecco L, Cerra M, Bond HM, Barbieri V, Venuta S. CD36 is rapidly and transiently upregulated on phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes. Analysis by a new monoclonal antibody (UN7). *Tissue Antigens*. 1998 Jun;51(6):671-5.
206. Romano MF, Lamberti A, **Tassone P**, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli P, Tuccillo F, Turco MC, Venuta S. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. *Blood*. 1998 Aug 1;92(3):990-5.
207. Cecco L, Bond HM, Bonelli P, Tuccillo F, Cerra M, **Tassone P**, Sorice R, Lamberti A, Morrone G, Venuta S. Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues. *Tissue Antigens*. 1998 May;51(5):528-35.
208. Petrella A, Doti I, Agosti V, Giarrusso PC, Vitale D, Bond HM, Cuomo C, **Tassone P**, Franco B, Ballabio A, Venuta S, Morrone G. A 5' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells. *Blood*. 1998 Jun 15;91(12):4554-60.
209. Bond HM, Bonelli P, Mesuraca M, Agosti V, Masone C, Cuomo C, Nisticò A, **Tassone P**, Tuccillo F, Cecco L, Iacopino L, Barbieri V, Cerra M, Costanzo FS, Morrone G, Venuta S. Identification by differential display of transcripts regulated during hematopoietic differentiation. *Stem Cells*. 1998;16(2):136-43.
210. **Tassone P**, Turco MC, Tuccillo F, Bonelli P, Morrone G, Cecco L, Cerra M, Bond H, Di Nicola M, Gianni AM, Venuta S. CD69 expression on primitive progenitor cells and hematopoietic malignancies. *Tissue Antigens*. 1996 Jul;48(1):65-8.
211. Romano MF, Lamberti A, Petrella A, Bisogni R, **Tassone PF**, Formisano S, Venuta S, Turco MC. IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. *J Immunol*. 1996 Mar 15;156(6):2119-23.
212. **Tassone P**, Bonelli P, Tuccillo F, Cecco L, Turco MC, Cerra M, Nigro M, Morrone G, Venuta S. Detection of an antigenic marker expressed by peripheral blood monocytes and platelets by a new monoclonal antibody, UN8. *Tissue Antigens*. 1995 Apr;45(4):288-91.
213. **Tassone P**, Bonelli P, Tuccillo F, Turco MC, De Rosa G, Morrone G, Cecco L, Cerra M, Petrella A, Nigro M, et al. Analysis of peripheral blood normal and malignant cells with the novel murine monoclonal antibody UN2. *Immunol Lett*. 1994 Sep;42(1-2):55-62.

214. Alfinito F, Lamberti A, Capobianchi MR, Nigro M, De Rosa G, **Tassone P**, Turco MC, Dianzani F, Venuta S. T cell growth-promoting activity of interferon-gamma. Mitogenic effect of the recombinant cytokine on cells from a human T-chronic lymphocytic leukemia. Leukemia. 1994 Aug;8(8):1294-300.
215. **Tassone P**, Bond H, Bonelli P, Tuccillo F, Valerio G, Petrella A, Lamberti A, Cecco L, Turco MC, Cerra M, et al. UN1, a murine monoclonal antibody recognizing a novel human thymic antigen. Tissue Antigens. 1994 Aug;44(2):73-82.
216. Romano MF, Bisogni R, Lamberti A, Turco MC, Petrella A, **Tassone P**, Van Lier R, Formisano S, Venuta S. Regulation of NF-kappa B nuclear activity in peripheral blood mononuclear cells: role of CD28 antigen. Cell Immunol. 1994 Jul;156(2):371-7.
217. **Tassone P**, Bonelli P, Tuccillo F, Bond HM, Turco MC, Morrone G, Cecco L, Cerra M, Venuta S. A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells. Immunol Lett. 1994 Feb;39(2):137-46.
218. Romano MF, Turco MC, Stanziola A, Giarrusso PC, Petrella A, **Tassone P**, van Lier R, Venuta S, Formisano S. Defect of interleukin-2 production and T cell proliferation in atopic patients: restoring ability of the CD28-mediated activation pathway. Cell Immunol. 1993 May;148(2):455-63.
219. **Tassone P**, Bond H, Bonelli P, Tuccillo F, Cecco L, Lamberti A, De Lorenzo F, Cerra M, Turco MC, Venuta S. UN-1, a murine monoclonal antibody recognizing a human thymocyte undescribed antigen. Pharmacol Res. 1992 Sep;26 Suppl 2:128-9.